Silo Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SILO research report →
Price Chart
About the company
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS).
- CEO
- Eric Weisblum
- IPO
- 2021
- Employees
- 3
- HQ
- Sarasota, FL, US
Get TickerSpark's AI analysis on SILO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.64M
- P/E
- -0.27
- PEG
- -0.00
- P/S
- 30.26
- P/B
- 0.33
- EV/EBITDA
- 0.36
- Div Yield
- 0.00%
- Gross Margin
- -474.31%
- Op Margin
- -8250.46%
- Net Margin
- -8269.53%
- ROE
- -81.74%
- ROIC
- -91.31%
Latest fiscal year · YoY change
- Revenue
- $72.10K+0.0%
- Gross Profit
- $-813,955-1328.4%
- Op Income
- $-4,280,662
- Net Income
- $-4,227,698+3.8%
- EPS
- $-7.50+58.0%
- OCF Growth
- -21.6%
- FCF Growth
- -21.6%
- 52W High
- $10.88
- 52W Low
- $1.30
- 50D MA
- $2.71
- 200D MA
- $4.98
- Beta
- 0.75
- RSI (14)
- 19
- Avg Volume
- 210.65K
No earnings-call transcripts are available for SILO yet.
- Free Float
- 94.8%
- Shares Outstanding
- 1.13M
- Float Shares
- 1.07M
of shares held by institutions
14 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 24.32K | ▲ 7.99K |
| Ifp Advisors, Inc | 175 | 0 |
Held by 10 ETFs
Biggest fund positions in SILO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 15, 25 | Weisblum Eric | buy | 2,500 |
| Dec 15, 25 | Weisblum Eric | buy | 2,500 |
| Nov 21, 25 | Weisblum Eric | buy | 1,000 |
| Nov 20, 25 | Weisblum Eric | buy | 1,000 |
| Nov 19, 25 | Weisblum Eric | buy | 4,500 |
| Nov 18, 25 | Weisblum Eric | buy | 7,500 |
| May 27, 25 | Weisblum Eric | buy | 10,000 |
| May 23, 25 | Linsley Wayne | other | 50,000 |
| May 23, 25 | Munoz Kevin | other | 50,000 |
| May 23, 25 | Ryweck Daniel E. | other | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SILO coverage
Recent articles, reports, and earnings notes.
No research on SILO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SILO report →Silo Pharma's QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility
globenewswire.com · Sep 30
Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
globenewswire.com · Sep 18
Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
globenewswire.com · Sep 9
InterCure (NASDAQ:INCR) & Silo Pharma (NASDAQ:SILO) Financial Review
defenseworld.net · Sep 8
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
globenewswire.com · Aug 18
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
globenewswire.com · Aug 6
Short Interest in Silo Pharma, Inc. (NASDAQ:SILO) Expands By 795.6%
defenseworld.net · Jul 27
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
globenewswire.com · Jul 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.